Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Letter to the Editor
2010:76:1;61-62
doi: 10.4103/0378-6323.58684
PMID: 20061736

Updosing of antihistamines to improve control of chronic urticaria

Kiran V Godse
 Shree Skin Centre, 21/22, L Market, Sector 8, Nerul, Navi Mumbai - 400 706, India

Correspondence Address:
Kiran V Godse
Shree Skin Centre, 21/22, L Market, Sector 8, Nerul, Navi Mumbai - 400 706
India
How to cite this article:
Godse KV. Updosing of antihistamines to improve control of chronic urticaria. Indian J Dermatol Venereol Leprol 2010;76:61-62
Copyright: (C)2010 Indian Journal of Dermatology, Venereology, and Leprology

Sir,

Nonsedating antihistamines are recommended as first line treatment for patients with urticaria. The current European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum (EAACI/GA 2 LEN/EDF) guidelines call for updosing of nonsedating antihistamines (up to four times the standard dose) in urticaria patients who do not respond satisfactorily to the standard doses. [1] There are a few studies to assess the efficacy of such a recommendation.

Twenty patients (12 females and eight males, age group 20-60 years, mean age 27.2 years) with chronic urticaria for at least six weeks and pruritus, wheal score of more than two were enrolled after an informed written consent. The exclusion criteria included physical urticaria, urticarial vasculitis, pregnant or lactating women, gastritis, a history of sensitivity to aspirin or NSAIDs and a history of aggravation of symptoms by pressure. Routine investigations like complete blood count, blood sugar, thyroid stimulating hormone (TSH) and urine examination were done to rule out infections before starting therapy. All 20 patients had chronic idiopathic urticaria of duration ranging from three months to two years (mean duration 14.8 months).

After a one-day washout without treatment we graded symptoms using the Urticaria activity score (UAS). The UAS consisted of the sum of the wheal number score and the itch severity score. [2] The wheal numbers were graded from 0 to 3 as follows: 0-< 10 small wheals (diameter, < 3 cm); 1-10 to 50 small wheals or < 10 large wheals (diameter,> 3 cm); 2->50 small wheals or 10 to 50 large wheals; and 3 - almost the whole body is covered. The severity of the itching was graded from 0 to 3 (0, none; 1, mild; 2, moderate; and 3, severe).

Sedation was graded from 0 to 3 (0, none; 1, mild; 2, moderate; and 3, severe). We recorded UAS at zero two and four weeks to monitor urticaria. All patients were started with levocetirizine 5 mg tablet at bed time. Patients were reviewed at weekly intervals of four weeks. For symptomatic patients, the dose of levocetirizine was doubled to two tablets at bed time at the end of one week and four tablets in two divided doses at the end of two weeks.

Investigations revealed microcytic anemia in two patients and raised thyroid stimulating hormone (TSH) in one patient. Average UAS was 4.5 at 0 weeks which came down to 2.2 at one week.

At the end of one week, eight patients out of 20 were symptomatic. We doubled the dose to 10 mg of levocetirizine at bedtime. At two weeks UAS was 1.2. At the end of two weeks two out of eight patients were symptomatic whose dose was doubled to 10 mg of Levocetirizine twice a day. At the end of four weeks UAS came down to less than 1.

Sedation was recorded as 0, mild or moderate or severe. One patient with 20 mg of levocetirizine complained of sedation, which was mild and one patient with 10 mg of levocetirizine complained of sedation which was also mild in nature. Twelve, six and two patients became symptom-free when administered 5, 10 and 20 mg levocetirizine respectively.

In a recent study, Levocetirizine 5 mg was significantly more efficacious than desloratadine 5 mg in the treatment of chronic idiopathic urticaria symptoms. [3] Another recent study from Germany showed that desloratadine at standard and high doses significantly improved objective signs of acquired cold urticaria provoked by cold exposure. Desloratadine at four times the standard dose significantly reduced acquired cold urticaria lesion severity versus 5 mg of desloratadine without an increase in adverse events. [4]

The EAACI/GA 2 LEN recommendation of using nonsedating H 1 antihistamines up to four fold above the recommended doses appears to be effective with mild sedation. The current approach of adding another antihistamine may be changed to updosing the same antihistamine for desirable results. Further studies are required to validate this observation.

References
1.
Zuberbier T, Bindslev-Jensen C, Canonica W, Grattan CE, Greaves MW, Henz BM, et al. EAACI/GA 2 LEN/EDF guideline: Management of urticaria. Allergy 2006;61:321-31.
[Google Scholar]
2.
Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: A single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol 2002;110:484-8.
[Google Scholar]
3.
Potter PC, Kapp A, Maurer M, Guillet G, Jian AM, Hauptmann P, et al. Comparison of the efficacy of levocetirizine 5 mg and desloratadine 5 mg in chronic idiopathic urticaria patients. Allergy 2009;64:596-604.
[Google Scholar]
4.
Siebenhaar F, Degener F, Zuberbier T, Martus P, Maurer M. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. J Allergy Clin Immunol 2009;123:672-9.
[Google Scholar]

Fulltext Views
551

PDF downloads
120
Show Sections